Lineage Cell Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $37,355 | $40,791 |
| Marketable securities | 13,474 | 14,990 |
| Accounts receivable | 790 | 891 |
| Prepaid expenses and other current assets | 1,351 | 2,485 |
| Total current assets | 52,970 | 59,157 |
| NONCURRENT ASSETS | ||
| Property and equipment, net | 2,517 | 2,566 |
| Operating lease right-of-use assets | 1,964 | 2,131 |
| Deposits and other long-term assets | 598 | 558 |
| Goodwill | 10,672 | 10,672 |
| Intangible assets, net | 31,700 | 31,700 |
| Deferred tax asset, net | 5,799 | 5,800 |
| TOTAL ASSETS | $106,220 | $112,584 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | $5,387 | $7,181 |
| Operating lease liabilities, current portion | 918 | 816 |
| Finance lease liabilities, current portion | 33 | 37 |
| Deferred revenues, current portion | 1,678 | 3,333 |
| Total current liabilities | 8,016 | 11,367 |
| LONG-TERM LIABILITIES | ||
| Deferred tax liability, net | 22 | 22 |
| Deferred revenues, net of current portion | 12,339 | 12,377 |
| Operating lease liabilities, net of current portion | 1,333 | 1,534 |
| Finance lease liabilities, net of current portion | 15 | 32 |
| Warrant liabilities | 24,697 | 43,906 |
| TOTAL LIABILITIES | 46,422 | 69,238 |
| Commitments and contingencies (Note 13) | ||
| SHAREHOLDERS’ EQUITY | ||
| Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common shares, no par value, 450,000 shares authorized as of June 30, 2026 and December 31, 2025; 252,907 and 243,122 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 535,717 | 515,467 |
| Accumulated other comprehensive loss | (4,473) | (3,920) |
| Accumulated deficit | (470,328) | (466,998) |
| Lineage's shareholders’ equity | 60,916 | 44,549 |
| Noncontrolling deficit | (1,118) | (1,203) |
| Total shareholders’ equity | 59,798 | 43,346 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $106,220 | $112,584 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.